Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | ALB | P02768 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.57 |
| ▸ | CCKBR | P32239 | 4/20 | 0.54 |
| ▸ | CNR1 | P21554 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.47 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.47 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.47 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.47 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5426761 | 0.93 | MEN1 (0.65) | MEN1LMNAALBKMT2ACHRM1 | |
| SCHEMBL5427058 | 0.85 | MEN1 (0.60) | MEN1LMNAALBKMT2ACHRM1 | |
| SCHEMBL14425343 | 0.78 | MEN1 (0.60) | MEN1LMNAALBKMT2ACHRM1 | |
| SCHEMBL7935883 | 0.78 | CHRM1 (0.74) | MEN1LMNAALBKMT2ACHRM1 | |
| SCHEMBL21272248 | 0.78 | CHRM1 (0.74) | MEN1LMNAALBKMT2ACHRM1 | |
| SCHEMBL10812464 | 0.74 | LMNA (0.74) | MEN1LMNAALBKMT2ACHRM1 | |
| Oxazepam SCHEMBL28100675 | 0.74 | LMNA (0.95) | MEN1LMNAALBKMT2ACHRM1 | |
| SCHEMBL11836983 | 0.74 | MEN1 (0.66) | MEN1LMNAALBKMT2ACHRM1 | |
| Oxazepam SCHEMBL528376 | 0.73 | LMNA (1.00) | MEN1LMNAALBKMT2ACHRM1 | |
| Oxazepam SCHEMBL5498881 | 0.73 | LMNA (1.00) | MEN1LMNAALBKMT2ACHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070185094-A1 | Novel 3-substitued-1,4-benzodiazepines | ASTON UNIVERSITY (GB) | 2007-08-09 | — | — | US | disclosed |
| US-20070185094-A1 | Novel 3-substitued-1,4-benzodiazepines | ASTON UNIVERSITY (GB) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185094-A1 | Novel 3-substitued-1,4-benzodiazepines | CCKBR, CCKAR, GABRB1 | MEN1 2746/4885LMNA 4248/4885ALB 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.